Incyte (INCY) Goodwill & Intangibles (2010 - 2026)
Incyte's (INCY) quarterly Goodwill & Intangibles came in at $236.2 million in Q2 2026, down 16.25% YoY from $282.0 million in Q2 2025, and down 2.87% on a QoQ basis from $243.2 million in Q1 2026.
Analysis
Incyte (INCY) Goodwill & Intangibles (2010 - 2026) Analysis & Trends
Incyte (INCY) has 17 years of Goodwill & Intangibles data on file, last reported at $236.2 million in Q2 2026.
- Quarterly Goodwill & Intangibles fell 16.25% year-over-year to $236.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $236.2 million (down 16.25% YoY) and the FY2025 annual result came in at $250.1 million, down 7.15% from the prior year.
- Goodwill & Intangibles retreated to $236.2 million in Q2 2026, from $243.2 million in the prior quarter.
- In the past five years, Goodwill & Intangibles ranged from a high of $301.0 million in Q1 2022 to a low of $236.2 million in Q2 2026.
- A 5-year average of $275.5 million and a median of $277.4 million in 2023 frame the typical range for Goodwill & Intangibles.
- Annual changes were most pronounced in 2025 — Goodwill & Intangibles grew 4.79% — and 2026, when it fell 16.25%.
- Tracing INCY's Goodwill & Intangibles over 5 years: stood at $284.8 million in 2022, then decreased by 1.99% to $279.1 million in 2023, then dropped by 3.49% to $269.4 million in 2024, then slipped by 7.15% to $250.1 million in 2025, then slipped by 5.57% to $236.2 million in 2026.
- The last three Goodwill & Intangibles figures came in at $236.2 million (Q2 2026), $243.2 million (Q1 2026), and $250.1 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn |
| 10 | Incyte | 25.59 Bn | 21.05 Bn | 1.57 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 236.20 Mn |
| Mar 31, 2026 | 243.16 Mn |
| Dec 31, 2025 | 250.13 Mn |
| Sep 30, 2025 | 275.01 Mn |
| Jun 30, 2025 | 282.01 Mn |
| Mar 31, 2025 | 263.20 Mn |
| Dec 31, 2024 | 269.40 Mn |
| Sep 30, 2024 | 275.59 Mn |
| Jun 30, 2024 | 269.13 Mn |
| Mar 31, 2024 | 273.43 Mn |
| Dec 31, 2023 | 279.14 Mn |
| Sep 30, 2023 | 284.84 Mn |
| Jun 30, 2023 | 290.55 Mn |
| Mar 31, 2023 | 296.25 Mn |
| Dec 31, 2022 | 284.81 Mn |
| Sep 30, 2022 | 290.20 Mn |
| Jun 30, 2022 | 295.58 Mn |
| Mar 31, 2022 | 300.96 Mn |
| Dec 31, 2021 | 306.35 Mn |
| Sep 30, 2021 | 156.14 Mn |